135 related articles for article (PubMed ID: 35762561)
1. Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study.
Chen M; Ding N; Mok Y; Mathews L; Hoogeveen RC; Ballantyne CM; Chen LY; Coresh J; Matsushita K
Clin Chem; 2022 Jul; 68(8):1084-1093. PubMed ID: 35762561
[TBL] [Abstract][Full Text] [Related]
2. Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation.
Rienstra M; Yin X; Larson MG; Fontes JD; Magnani JW; McManus DD; McCabe EL; Coglianese EE; Amponsah M; Ho JE; Januzzi JL; Wollert KC; Fradley MG; Vasan RS; Ellinor PT; Wang TJ; Benjamin EJ
Am Heart J; 2014 Jan; 167(1):109-115.e2. PubMed ID: 24332149
[TBL] [Abstract][Full Text] [Related]
3. Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study).
Norby FL; Tang W; Pankow JS; Lutsey PL; Alonso A; Steffen BT; Chen LY; Zhang M; Shippee ND; Ballantyne CM; Boerwinkle E; Coresh J; Folsom AR
Am J Cardiol; 2021 Dec; 161():42-50. PubMed ID: 34794617
[TBL] [Abstract][Full Text] [Related]
4. Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Bansal N; Zelnick LR; Soliman EZ; Anderson A; Christenson R; DeFilippi C; Deo R; Feldman HI; He J; Ky B; Kusek J; Lash J; Seliger S; Shafi T; Wolf M; Go AS; Shlipak MG;
Am J Kidney Dis; 2021 Jun; 77(6):907-919. PubMed ID: 33309861
[TBL] [Abstract][Full Text] [Related]
5. Refining Prediction of Atrial Fibrillation Risk in the General Population With Analysis of P-Wave Axis (from the Atherosclerosis Risk in Communities Study).
Maheshwari A; Norby FL; Soliman EZ; Koene R; Rooney M; O'Neal WT; Alonso A; Chen LY
Am J Cardiol; 2017 Dec; 120(11):1980-1984. PubMed ID: 28941601
[TBL] [Abstract][Full Text] [Related]
6. 6-year change in high sensitivity cardiac troponin T and the risk of atrial fibrillation in the Atherosclerosis Risk in Communities cohort.
Li L; Selvin E; Hoogeveen RC; Soliman EZ; Chen LY; Norby FL; Alonso A
Clin Cardiol; 2021 Nov; 44(11):1594-1601. PubMed ID: 34545585
[TBL] [Abstract][Full Text] [Related]
7. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study.
Aronis KN; Zhao D; Hoogeveen RC; Alonso A; Ballantyne CM; Guallar E; Jones SR; Martin SS; Nazarian S; Steffen BT; Virani SS; Michos ED
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29246963
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.
Filion KB; Agarwal SK; Ballantyne CM; Eberg M; Hoogeveen RC; Huxley RR; Loehr LR; Nambi V; Soliman EZ; Alonso A
Am Heart J; 2015 Jan; 169(1):31-8.e3. PubMed ID: 25497245
[TBL] [Abstract][Full Text] [Related]
9. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies.
Sinner MF; Stepas KA; Moser CB; Krijthe BP; Aspelund T; Sotoodehnia N; Fontes JD; Janssens AC; Kronmal RA; Magnani JW; Witteman JC; Chamberlain AM; Lubitz SA; Schnabel RB; Vasan RS; Wang TJ; Agarwal SK; McManus DD; Franco OH; Yin X; Larson MG; Burke GL; Launer LJ; Hofman A; Levy D; Gottdiener JS; Kääb S; Couper D; Harris TB; Astor BC; Ballantyne CM; Hoogeveen RC; Arai AE; Soliman EZ; Ellinor PT; Stricker BH; Gudnason V; Heckbert SR; Pencina MJ; Benjamin EJ; Alonso A
Europace; 2014 Oct; 16(10):1426-33. PubMed ID: 25037055
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.
Fashanu OE; Norby FL; Aguilar D; Ballantyne CM; Hoogeveen RC; Chen LY; Soliman EZ; Alonso A; Folsom AR
Am Heart J; 2017 Oct; 192():19-25. PubMed ID: 28938960
[TBL] [Abstract][Full Text] [Related]
11. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Yusuf S; Siegbahn A; Wallentin L
Am Heart J; 2017 Aug; 190():94-103. PubMed ID: 28760218
[TBL] [Abstract][Full Text] [Related]
12. NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach.
Svennberg E; Lindahl B; Berglund L; Eggers KM; Venge P; Zethelius B; Rosenqvist M; Lind L; Hijazi Z
Int J Cardiol; 2016 Nov; 223():74-81. PubMed ID: 27541645
[TBL] [Abstract][Full Text] [Related]
13. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas.
Pol T; Hijazi Z; Lindbäck J; Alexander JH; Bahit MC; De Caterina R; Eikelboom JW; Ezekowitz MD; Gersh BJ; Granger CB; Hylek EM; Lopes R; Siegbahn A; Wallentin L
Open Heart; 2021 Mar; 8(1):. PubMed ID: 33741689
[TBL] [Abstract][Full Text] [Related]
15. Association of White Blood Cell Count and Differential with the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study.
Misialek JR; Bekwelem W; Chen LY; Loehr LR; Agarwal SK; Soliman EZ; Norby FL; Alonso A
PLoS One; 2015; 10(8):e0136219. PubMed ID: 26313365
[TBL] [Abstract][Full Text] [Related]
16. Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study.
Alonso A; Misialek JR; Eckfeldt JH; Selvin E; Coresh J; Chen LY; Soliman EZ; Agarwal SK; Lutsey PL
J Am Heart Assoc; 2014 Sep; 3(5):e001082. PubMed ID: 25237047
[TBL] [Abstract][Full Text] [Related]
17. Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study.
Xiao J; Persson AP; Engström G; Johnson LSB
BMC Cardiovasc Disord; 2021 Mar; 21(1):134. PubMed ID: 33711943
[TBL] [Abstract][Full Text] [Related]
18. Association of Peripheral Artery Disease With Incident Atrial Fibrillation: The ARIC (Atherosclerosis Risk in Communities) Study.
Bekwelem W; Norby FL; Agarwal SK; Matsushita K; Coresh J; Alonso A; Chen LY
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29666066
[TBL] [Abstract][Full Text] [Related]
19. American Heart Association's Life Simple 7 and Risk of Atrial Fibrillation in a Population Without Known Cardiovascular Disease: The ARIC (Atherosclerosis Risk in Communities) Study.
Garg PK; O'Neal WT; Chen LY; Loehr LR; Sotoodehnia N; Soliman EZ; Alonso A
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650711
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers Associated with Atrial Fibrillation in Patients with Ischemic Stroke: A Pilot Study from the NOR-FIB Study.
Tancin Lambert A; Kong XY; Ratajczak-Tretel B; Atar D; Russell D; Skjelland M; Bjerkeli V; Skagen K; Coq M; Schordan E; Firat H; Halvorsen B; Aamodt AH
Cerebrovasc Dis Extra; 2020; 10(1):11-20. PubMed ID: 32028277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
